In June 2026, Shanghai hosted the 24th World Pharmaceutical Ingredients China Exhibition (CPhI China). As one of the most influential global events in the pharmaceutical industry, the exhibition gathered pharmaceutical manufacturers, raw material suppliers, technical service providers, and industry experts from around the world. At the same time, participants discussed the latest trends in pharmaceutical raw materials, intermediates, biopharmaceuticals, and green production technologies.
At this international platform, our company presented its core product—high-quality coconut shell activated carbon for pharmaceutical applications. In particular, we highlighted its strong performance in purification, decolorization, and refining processes. As a result, our booth attracted a large number of professional visitors who actively engaged in technical discussions and product inquiries.
Strengthening Pharmaceutical Purification Applications and Core Value
Global pharmaceutical manufacturers continue to raise requirements for product quality, safety, and environmentally friendly production. Therefore, purification and separation processes now play a more critical role in pharmaceutical manufacturing.
Our pharmaceutical-grade coconut shell activated carbon uses premium raw materials and advanced production technology. Moreover, it features a highly developed microporous structure, large specific surface area, and strong adsorption selectivity. These characteristics allow the product to effectively remove organic impurities, pigments, odors, and trace contaminants during production. As a result, customers achieve higher product purity and more stable quality.
In addition, our products serve a wide range of pharmaceutical applications and support consistent production performance under different process conditions. Pharmaceutical manufacturers rely on our activated carbon to improve process stability and meet strict quality standards.
Strong On-Site Engagement and High International Interest
During the exhibition, pharmaceutical companies, distributors, and industry partners from Asia, Europe, the Middle East, Africa, and South America visited our booth. Meanwhile, our technical team actively engaged with visitors and discussed key topics such as process optimization, impurity control strategies, adsorption material selection, and production cost reduction.
Furthermore, many customers evaluated the performance of activated carbon in different pharmaceutical systems. They focused on filtration efficiency, adsorption capacity, product purity control, and post-treatment efficiency. Our technical team provided detailed explanations based on real application cases. In addition, we offered customized technical recommendations for different production needs.
Through direct communication and sample discussions, we received strong interest from multiple customers. Consequently, several partners confirmed their intention to conduct sample testing and explore long-term cooperation. This created a solid foundation for future business development.
Expanding Global Market Presence and High-End Applications
By participating in CPhI China, our company strengthened its connections with global pharmaceutical customers. At the same time, we gained deeper insights into the increasing demand for high-performance activated carbon in pharmaceutical applications.
As the pharmaceutical industry continues to move toward higher purity standards, greener production processes, and greater efficiency, performance requirements for adsorption materials continue to rise. Therefore, our company continues to invest in research and process optimization. Moreover, we focus on improving adsorption capacity, mechanical strength, impurity control, and process adaptability.
In the future, we will continue to focus on pharmaceutical and high-end fine chemical markets. We will expand the application of our activated carbon across the global pharmaceutical supply chain. As a result, we aim to deliver more efficient, stable, and environmentally friendly purification solutions.
Outlook
Our participation in CPhI China served as an important industry communication platform. More importantly, it marked a key step in our global expansion strategy. Through in-depth discussions and cooperation exploration with international customers, we strengthened our commitment to a development strategy driven by “quality and innovation.”
Moving forward, we will continue to focus on customer needs. At the same time, we will improve product performance and service capabilities. Ultimately, we aim to support the global pharmaceutical industry in achieving higher-quality and more sustainable development.